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1. Introduction 
The initiating point to manage pregnancy in lupus patient is ideally before the onset of 
pregnancy. Therefore, at preconception counseling, the physician not only estimates the risk 
profile of the patients but also reviews their drugs. This is to avoid known teratogenic 
drugs, to discontinue certain medications and to initiate other drugs as a golden goal to 
protect the mother and fetus from adverse effects of these medications. Hence, it is essential 
to observe the mother at least six months before attempting conception for a better outcome 
in lupus pregnancy. 
The management of SLE pregnancy should be a multidisciplinary approach and needs 
good coordination and follow-ups with experts in the field like rheumatologist, 
obstetrician who is experienced in dealing with high risk pregnancies and nephrologist if 
the renal impairment is also present. Therefore, all lupus pregnancies should be closely 
monitored. 
This chapter covers general guidelines for the management of SLE during Pregnancy and 
post partum period in addition to safety of contraceptive methods in lupus women. 
2. Management issues  
Once the pregnancy test results are positive we should have a baseline evaluation of the 
disease activity, its severity and major organ involvement [Table1]. 
 Prenatal care visits: Every 4 weeks up to 20 weeks, then every 2 weeks until 28 weeks, 
then weekly until delivery. 
SLE presents several challenges in managing a pregnant woman and her fetus, as SLE 
affects almost every organ system in the body and shows a broad spectrum of disease 
manifestations ranging from mild to life-threatening conditions [Boumpas, 1995]. 
Due to the improvement of treatment modalities more and more women with this disease 
are able to become pregnant.  Pregnancy outcomes have improved dramatically over the last 
40 years, with a decrease in pregnancy loss rate from a mean of 43%   in 1960-1965 to 17%  
in 2000 - 2003 [Clark, 2005]. 
Pregnant patients with SLE on immunosuppressive therapy need prophylaxis for infection, 
(including antibiotics for invasive procedures), and immunization with influenza & 
pneumococcal vaccine.  
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  Baseline CBC, electrolytes, serum creatinine, liver enzymes, uric acid. 
 Fasting blood glucose, fasting lipid profile if at high risk, for example if 
patient is nephritic or on steroids 
 Normal antenatal check up 
 ANA, Anti-DsDNA, anti-Ro and anti-La, antibody titers 
 Complements levels (C3,C4,CH50) 
 Anticardiolipin antibodies, lupus anticoagulant and ┚2 glycoprotein 
 Urinalysis, 24-hour urine collection for measurement of protein and 
creatinine clearance 
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 Baseline laboratory studies 
 Anti-DsDNA 
 Complements levels (C3,C4,CH50) , urinalysis 
 Obstetric ultrasound: Every 4 weeks from 20 weeks of gestation until 
delivery “to monitor fetal growth” 
 Mother with positive Anti-Ro and/or Anti-La antibodies, serial fetal 
echocardiography between 16-36 weeks of gestation 
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  Repeat laboratory studies  
 Urinalysis, 24-hour urine protein collection if proteinuria is present 
 Weekly fetal non-stress test (NST) and/or biophysical profile (BPP) scoring 
from 28 weeks gestation 
 Fetal Doppler ultrasonography to be done in presence of intrauterine 
growth restriction 
EACH 
VISIT 
 Careful blood pressure measurement 
 Urine dipstick for proteinuria 
Table 1. Guidelines for assessment of pregnant patients with lupus 
2.1 Safety of medications 
SLE is common in women of childbearing age. Physicians should be aware of which 
medications to be used safely at preconception & conception, and effects on infants exposed 
to certain drugs. 
The Food and Drug Administration (FDA) has a classification system for pregnancy risk 
(Table 2). The pharmacological management of SLE is challenging as it has an unpredictable 
clinical course, with the variable organ system involvement and the lack of clear 
understanding of disease pathogenesis [Francis L, 2009].  
2.1.1 Antihypertensive drugs 
Hypertensive disorders of pregnancy are the leading cause of maternal mortality and 
morbidity.  Blood pressure tends to decrease in the first and second trimesters of pregnancy.  
The most appropriate blood pressure threshold and goal of antihypertensive treatment are 
controversial.  For women with severe hypertension (defined as a sustained systolic BP of 
>160mmHg and/or a diastolic BP of > 110mmHg), there is consensus that antihypertensive 
therapy should be given to lower the maternal risk of central nervous system complications.  
The target BP of safety in Pregnancy is less than 140/90 mm of Hg. 
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                           United States FDA Pharmaceutical Pregnancy Categories 
Pregnancy 
Category A 
Adequate and well-controlled human studies have failed to demonstrate a 
risk to the fetus in the first trimester of pregnancy (and there is no evidence 
of risk in later trimesters). 
Pregnancy 
Category B 
Animal reproduction studies have failed to demonstrate a risk to the fetus 
and there are no adequate and well-controlled studies in pregnant women 
OR Animal studies have shown an adverse effect, but adequate and well-
controlled studies in pregnant women have failed to demonstrate a risk to 
the fetus in any trimester. 
Pregnancy 
Category C 
Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential 
benefits may warrant use of the drug in pregnant women despite potential 
risks. 
Pregnancy 
Category D 
There is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but 
potential benefits may warrant use of the drug in pregnant women despite 
potential risks. 
Pregnancy 
Category X 
Studies in animals or humans have demonstrated fetal abnormalities and/or 
there is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience, and the risks involved in use 
of the drug in pregnant women clearly outweigh potential benefits. 
Table 2. United States FDA pharmaceutical pregnancy categories 
The bulk of evidence relates to use of parenteral hydralazine or labetalol, and oral 
nifedipine, labetalol or methyldopa [Magee, 2011].  It is essential to keep the blood pressure 
in the normal range.  Patients with new onset hypertension in pregnancy should be 
evaluated for PET. The medications that are best studied are methyldopa and labetalol.  
Methyldopa is the only antihypertensive agent for which there has been long-term follow-
up of children exposed in utero [Antonio, 2011]. 
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers should be 
avoided prior to conception as they are contraindicated and cannot be considered safe. And 
these drugs are also associated with higher incidence of fetopathy [Cooper, 2006]. 
2.1.2 Aspirin  
Treatment with low doses of Aspirin during pregnancy would be indicated in women  
with SLE, APS, hypertension, history of preeclampsia, and renal disease. Aspirin can cross 
the placenta and can cause congenital anomalies in animals but these are rare in human 
beings. Several large prospective studies failed to confirm a significant increase in  
cleft palate or congenital anomalies [Jick, 1981].  Low dose of Aspirin is safe throughout 
pregnancy. Women who took Aspirin had a significantly lower risk of preterm delivery than 
those treated with placebo but there is no significant difference in perinatal mortality 
[Kozer, 2003]. 
A meta-analysis showed reduction in the risk of preeclampsia, preterm delivery before 34 
weeks of gestation and serious adverse outcomes among women taking low-dose Aspirin or 
dipyridamole [Aski, 2007]. 
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
486 
Aspirin has anti-prostaglandin effects and therefore it is better discontinued 8 weeks prior 
the expected delivery to avoid prolonged gestation and labour. This also reduces bleeding 
during delivery and bleeding complications in the fetus. 
2.1.3 Non-steroidal anti-inflammatory drugs (NSAIDs)  
The effect of NSAIDs use on the fetus depends upon the term of pregnancy.  A number of 
cohort studies looking at the teratogenic risk of NSAIDs use during the first trimester have 
not found an increased risk of congenital malformation [Janssen, 2000].  However, due to 
the shared property of inhibition of prostaglandin synthesis, adverse effects such as 
constriction of the ductus arteriosus in utero, persistent pulmonary hypertension, renal 
dysfunction in the neonate, increased maternal blood loss, and prolongation of pregnancy & 
labour are possible when administered to pregnant patients. NSAID should be given in the 
lowest effective dose, and should be withdrawn before 8 weeks of expected date of delivery 
[Ostensen, 1994]. 
Prostaglandins (PGs) increase uterine contractions, enhance platelet aggregation and 
increase the fetal renal blood flow. Therefore, NSAIDs by inhibiting the PG synthesis, may 
decrease the fetal urinary output. NSAIDs, by inhibiting cyclooxygenase, decrease the PG 
synthesis.  
If NSAID is clinically indicated in the first or second trimester, Ibuprofen would be the 
preferred one. 
NSAIDs can potentially inhibit contractions and thereby prolong gestation. Because of the later 
effect, indomethacin, a potent NSAID, has been used in the treatment of premature labour. 
NSAID inhibition of fetal urinary output may cause oligohydramnios and this is reversible 
once the NSAID is stopped. Inhibition of prostaglandin synthesis by NSAID may also result in 
constriction of the ductus arteriosus which can cause fetal pulmonary hypertension. In the 
studies with indomethacin, these effects were first noticed in the 27th week of gestation but 
most marked in the 32nd week of gestation [Janssen, 2000; En Hams, 2002]. 
2.1.4 Anti-malarial drugs  
Hydroxychloroquine: “HCQ” is the commonest anti-malarial drug used in SLE.  It has been 
used in pregnancy for malarial prophylaxis with no teratogenic effects [Lewis, 1973].  
HCQ main mechanism of action is through inhibition of antigen processing and 
inflammatory cytokine release [Fox, 1996].  These drugs are highly effective for discoid 
lupus erythematosus (DLE) cutaneous lesions.  HCQ improves photosensitive skin lesions 
and prevents lupus flares [Gladman, 1998].  Studies have shown that HCQ can prevent renal 
and central nervous system lupus.  It also exhibits the role of a prophylactic agent against 
some of the major morbidities of SLE and its treatment, namely hyperlipidemia, diabetes 
mellitus and thrombosis [Mpetvi, 1996]. 
As it has a long half life of eight weeks and accumulates in the body, discontinuation of 
drug immediately after conception does not prevent the exposure of fetus to the drug. A 
systemic review of hydroxychloroquin use in pregnant patients with auto-immune diseases 
from 1980 to 2007 showed that HCQ is not associated with any increased risk of congenital 
defects, spontaneous abortions, fetal death, prematurity or decreased number of live births 
in patients with auto-immune disease [Sperber, 2009]. 
RA Levy et al observation in prospective randomized placebo controlled study revealed  
that HCQ can be used safely in pregnancy with additional benefits on the disease activity. 
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The neonatal results (Apgar score, weight and gestation age) were significantly better in  
the HCQ group with absence of teratogenic effects after 3 years of follow-up in children 
[Levy, 2001]. 
HCQ is often needed to manage hyperactivity of the disease, as it appears to be safe and 
decreases lupus activity during pregnancy. 
2.1.5 Corticosteroids  
It is relatively safe to use during pregnancy but we should pay attention to maternal 
hypertension, gestational diabetes, infection, weight gain, acne and proximal muscle 
weakness. Therefore close monitoring with the use of the lowest possible dose of 
corticosteroid needed to control disease flare along with vitamin D and calcium 
supplements. Although animal studies have suggested an increased risk of oral clefts 
associated with glucocorticoid, several human studies have failed to demonstrate either 
teratogenic or toxic effects [Raybum, 1992]. 
Corticosteroids (Prednisalone, Prednisone, and Methylprednisolone) are metabolized by 
placenta II-beta-hydroxy steroid dehydrogenase (II-beta-HSD) which converts active 
cortisone to inactive cortisone.  Therefore, fetal blood levels are approximately 10% of the 
mother’s level [69], while fluorinated corticosteroids (dexamethasone and betamethasone) 
do cross the placenta in an un-metabolized form. Therefore, neonates should be monitored 
for evidence of adrenal insufficiency. 
If our concern is to treat the mother, the most suitable corticosteroid is prednisalone, 
prednisone or methylprednisolone. But if our concern is to treat the fetus, then it is either 
dexamethasone or betamethasone, which is not inactivated by placental 11-beta 
hydroxysteroid dehydrogenase and are best suited for fetal treatment as they clearly reduce 
the risk of death and respiratory distress syndrome in the preterm infants [NICHHD, 1994]. 
It is currently recommended that obstetricians give only a single course of antenatal 
corticosteroids to pregnant women to enhance lung maturity instead of giving repeated 
doses as weekly courses of antenatal corticosteroid which did not reduce composite 
neonatal morbidity compared with a single course of treatment.  Weekly courses of 
antenatal corticosteroids should not be routinely prescribed for women at risk of preterm 
delivery [Guinn, 2001]. 
Separate meta-analysis of the data in the Cochrane review showed that betamethasone and 
not dexamethasone reduces neonatal morbidity [Crowley, 2000] as betamethasone may offer 
better long-term neuro developmental outcome for the fetus [Lee BH, 2008]. 
In patients with chronic corticosteroid treatment during pregnancy, “stress doses” of 
hydrocortisone are recommended for prolonged labor, delivery, caesarian section, or any 
emergency surgery. 
2.1.6 Immunosuppressive agents  
Cyclophosphamide 
Fetal survival is strongly in doubt when cyclophosphamide is required to treat lupus 
during pregnancy.  The high risk for loss of the fetus should be discussed with the patient 
prior to administration of cyclophosphamide [Clowse MEB, 2005]. Patients undergoing 
therapy with cyclophosphamide must avoid pregnancy during therapy, especially in the 
first trimester. Attempts of conception should be delayed until three months after 
cessation of therapy. 
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It is a teratogenic drug and should only be used after the first trimester unless the mother’s 
life is threatened [Briggs, 2005].  To avoid fetal loss and malformations from inadvertent first 
trimester exposure during cyclophosphamide therapy, strict adherence to birth control 
measures, as well as a pregnancy test prior to pulse therapy should be the routine practice 
[Clowse MEB, 2005]. 
In patients with life-threatening disease, the use of cyclophosphamide may be considered 
after the first trimester. 
Azathioprine (AZA) 
It is a purine analogue which interferes with the synthesis of nucleic acid. Although 
azathioprine crosses the placenta, only minimal amount reaches the fetal blood.  
Azathioprine metabolites 6-thioguanine nucleotide (6-TGN) was slightly lower in the RBC 
of the infant than the mother, while other azathioprine metabolite 6-methylmercaptopurine 
(6-MMP) could not be detected in the infant which means the placenta forms a (relative) 
barrier to AZA and its metabolites [Da Boer, 2006]. 
Methotrexate (MTX) 
It is contraindicated in pregnancy (FDA risk category x) because of severe adverse effects on 
both the fetus and the course of the pregnancy [Janssen, 2000].  Plan for conception should 
be taken after three months of methotrexate withdrawal as the active metabolites remain in 
the body for approximately two months after its discontinuation. MXT acts as a folate 
antagonist and therefore leads to folate depletion during MTX treatment. Hence folate 
supplementation should be continued throughout pregnancy. 
Mycophenolate mofetil (MMF)  
It is mainly used in renal lupus, and there are very few data concerning its use.  It is 
advisable to switch to azathioprine before conception.MMF currently used as a maintenance 
therapy for lupus nephritis, and also used for resistant skin lupus, lupus disease activity and 
hematological manifestations [Karim, 2002]. 
Based on toxicity shown in animal studies, patients should not become pregnant while 
taking MMF.  Women taking MMF who wish to become pregnant should discontinue the 
drug at least 6 weeks prior to conception. 
Cyclosporine (CSA)  
Cyclosporine is an immunosuppressant that was first used for pregnant transplant rejection.  
CSA does not appear to be a major human teratogen.  It may be associated with increased 
rate of prematurity [Bar, 2001]. 
2.1.7 Biologic agents  
Anti-tumor necrosis factor alpha (Anti-TNFα)  
Maternal immunoglobulin (IgG) concentrations in fetal blood increase from early second 
trimester through term as maternal antibodies transported across the placenta to protect the 
new born.  Most antibodies are acquired during the third trimester.  The three commercially 
available TNF-┙ inhibitors (infliximab, etanercept, adalimumab) constructed based on IgG, 
so that these can cross the placenta to the fetus in the first trimester and more efficiently 
during the second and third trimesters.  
Anti-TNF┙ medications have led to improvements in the treatment of inflammatory 
conditions.  The safety of these drugs during pregnancy is an important issue.  Prospectively 
www.intechopen.com
 
Management of Pregnant Lupus 
 
489 
collected data appear to be reassuring. However, an analysis of the FDA-reported anomalies 
has raised some questions.  It appears that significant levels of these drugs cross the placenta 
as the pregnancy nears term, but very little passes into the breast milk.  Prior to usage of 
these medications during pregnancy, their risks and benefits, other treatment options, and 
the ongoing inflammatory conditions, all must be carefully weighed by both doctor and 
patient [Clowse, 2010]. 
The FDA classified these biological agents as pregnancy risk category B, which means that 
no adverse pregnancy effect have been observed in animals studies but there have been 
insufficient controlled human studies.  The published experience with anti-TNF during 
pregnancy consists of a limited number of case reports, series, and ongoing registry data. 
Many patients have experienced successful pregnancies following TNF exposure.  Patients 
with unplanned pregnancies exposed to TNF inhibitors either before or after conception 
does not require termination of pregnancy unless additional maternal-fetal assessments 
suggest untoward or dangerous effects. While most of the existing data on TNF inhibitors 
use in pregnancy have been generated during conception and the first trimester of 
pregnancy, there is limited and inadequate information regarding their use throughout 
pregnancy or during breast feeding [Ali, 2010]. At present the use of biological agents 
cannot be recommended throughout pregnancy [Sorensen, 2011]. Therefore, it is better to 
stop anti-TNF once the pregnancy test is positive.  
Rituximab   
It is a chimeric anti-CD20 monoclonal ┚-cell depleting antibody. One should continue to 
counsel the women to avoid pregnancy for up to 12 months after rituximab exposure 
[Chakra Varty, 2011]. Therefore, it must be withdrawn before a planned pregnancy.  
Experience with rituximab during pregnancy is too limited to allow any statement on safety 
in pregnancy.  When administered in the second and third trimester, ┚-cell depletion occurs 
in the fetus.  Long-term studies on ┚-cell and immune function of children exposed in utero 
are lacking [Ostensen, 2008].  Rituximab is potentially unsafe because of reversible fetal 
cytopenias including ┚-cell depletion have occurred in infants of mothers who are given this 
drug during pregnancy [Doria, 2008]. 
2.1.8 Other therapeutic measures  
Intravenous Immunoglobulin (IVIG)  
During pregnancy, intravenous Immunoglobulin (IVIG) may be used if needed to control 
severe maternal lupus activity.  It does not appear to cause any fetal abnormalities.  This 
drug has been used for many years without any adverse effects [Bonnie, 1995].  In a study 
comparing twelve SLE-suffered pregnant patients from recurrent spontaneous abortion 
(RSA) treated with a high dose of IVIG as against twelve SLE-RSA pregnant patients treated 
with prednisalone and NSAIDs showed a beneficial clinical response following IVIG 
treatment in all patients, and the antibodies and complement levels also tended to normalize 
in most of the patients. So IVIG is considered safe and effective [Perricone, 2008].  
Plasmapheresis (PP)  
It is safe, expensive, labor-intensive procedure. Its absolute indications include hyper 
viscosity, cryoglobulinemia, pulmonary hemorrhage and TTP. PP may be useful in 
cyclophosphamide resistant and serious organ–threatening disease [Erickson, 1994; 
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Wallance, 2001]. It is safe in children and pregnant females [Wallance, 2001]. Removal of 
anticardiolipin antibodies or Lupus anticoagulant by plasmapheresis during pregnancy or 
its use in those with recurrent thromboembolic episodes has been the subject of numerous 
case reports but no prospective studies have been done. However, it is believed that 
plasmapheresis during pregnancy definitely removes anticardiolipin antibodies. 
[Koblayash, 1992].  
Aphaeresis is well tolerated among pregnant patients, and has been used to remove 
antiphspholipid antibodies and Anti-Ro (SSA). It has been suggested that weekly 
Plasmapheresis can decrease anti-52 kD reactivity and might prevent heart block if it is 
initiated in the first trimester [Vonderleij, 1994]. 
2.2 Delivery 
Systemic lupus erythematosus is not an indication for delivery by cesarean section; although 
high rates of preeclampsia and cesarean section in connective tissue disease pregnancies 
were documented in a population based study they mainly emphasized on the importance 
of monitoring and obstetrical interventions [John Fredrick, 2000]. 
A team approach guarantees to the pregnant women with SLE, a safe vaginal delivery and 
allows performing a cesarean section for obstetric indications only.   
In a study of 555 lupus pregnancies, cesarean sections were needed in 38.2% of these 
patients versus 19.7% of controls [Yasmeen, 2001] .The major indications for cesarean section 
are fetal distress and maternal preeclampsia. One should remember that, general 
anaesthesia in a pregnant women has a mortality rates of 16.7% which is much greater than 
that of epidural or subarachnoid anesthesia [Hawkins, 1997]. It is ideal that the obstetrician, 
the anesthesiologist and the rheumatologist should evaluate the condition of the mother and 
the fetus and plan the type of delivery accordingly. 
Generally , in the case of vaginal delivery the anesthesiologist can guarantee an epidural 
analgesia with no greater risks than those of  a healthy parturient. In the event of cesarean 
section we can usually administer a neuro-axial anesthesia as the preferred type of 
anesthesia reserving the general anesthesia only to obstetrical emergencies [Rawetz, 2004]. 
The indications for cesarean section include maternal causes such as avascular necrosis of 
the hips with inadequate hip abduction, placental abruption or fetal causes such as fetal 
distress, prolapsed umbilical cord, abnormal non- stress test,  cephalo-pelvic disproportion 
and transverse presentation. Delivery should be in a hospital which has neonatal intensive 
care unit. Pregnant women with lupus treated with systemic steroid within two years of the 
anticipated delivery should receive steroid stress coverage during delivery.  
2.3 Puerpurium  
The optimum management is not over with the birth of a healthy baby. In fact, postpartum 
period should be considered as a high risk for pregnant lupus patients with several possible 
complications ahead. First, the mother can suffer a lupus flare, since several studies have 
confirmed the postpartum period is particularly high risk for increased lupus activity. A 
close surveillance in the first four weeks after delivery is thus warranted, especially in 
women with recent activity or with a previous history of severe disease. However no 
specific prophylactic therapy, such as increasing the dose of steroid, is recommended. 
The puerpurium has also high risk for thromboembolic complications. This is especially true 
in women with APS, in whom adequate thrombo-prophylaxis with low molecular weight 
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heparin (LMWH) should be extended 4-6 weeks after delivery. Those with previous history 
of thrombosis can be back on their usual full anticoagulant therapy within first 2-3 days 
postpartum. It should be remembered that both warfarin and heparin are safe during 
lactation [Guillermo Ruiz-Irastorza et al, 2009].   
2.4 Lactation  
The increasing prevalence of breast feeding along with the increased frequency of 
pregnancies in females with chronic medical conditions have increased the number of 
patients who face possible harmful effects on the newborn of medication excreted in breast 
milk.  Generally, drugs known to be extensively protein bound are excreted in breast milk to 
a lesser extent than drugs that are poorly bound to plasma proteins. 
 
             
         Factors related to breast milk 
 
Milk composition (lipid and protein concentrations) 
             
         Factors related to the mother 
 
Renal and hepatic excretion 
Dose and duration of treatment 
Route of administration 
           
           Factors related to the infant 
 
Age 
Drug Absorption 
Renal and hepatic excretion 
Volume of milk intake 
Safety of the drug for the infant 
            
            Factors related to the drug 
 
Solubility in water and lipid 
Molecular size 
Oral bioavailability 
Toxicity 
Suppressive effect on milk production 
Long-acting drug x short-acting drug 
Table 3. Factors that determine the safety of the drugs used during breastfeeding.  (Adapted 
from Howard & Lawrence, 1999.) 
There are multiple factors that determine the concentration of the drug in breast milk  
which include maternal, infant, and drug-related factors [Bowes, 1980] as shown in the table 
(Table 3). It is recommended to take the medication immediately after breastfeeding the 
baby, to ensure least possible concentration of the drug in breast milk.  Safety of medication 
is very important during lactation.  
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2.4.1 Aspirin 
Nursing mothers should avoid large doses of Aspirin.  The American Academy of Pediatrics 
recommends that Aspirin be used cautiously by the mother of the nursing infant and large 
doses of it should be avoided [Pediatrics, 1994]. 
2.4.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
The American Academy of Pediatrics considers Ibuprofen, Indomethacin, and Naproxen to 
be compatible with breastfeeding [Pediatrics, 1994], although most NSAIDs do not achieve 
high concentrations in breast milk [Ostensen, 1996].  Ibuprofen presents extremely low level 
in breast milk and has very short half-life; therefore it is considered to be a reasonable choice 
as an analgesic in the lactating women. 
2.4.3 Hydroxychloroquin (HCQ) 
The amount of HCQ received by children through lactation seems to be very low.  HCQ 
should probably be maintained throughout pregnancy in patients with SLE as it is also safe 
in breastfeeding [Cosedoat, 2005]. The American Academy of Pediatrics classifies the drug 
as compatible with breastfeeding.  Excretion into breast milk was very low (0.2mg/kg/day) 
and this level is not thought to be toxic [Costedoat, 2002].  Drug levels in milk reached a 
peak 2 hours after ingestion of hydroxychloroquine and declined after 9 hours.  It was 
estimated that a nursing child would ingest between 0.06-0.2mg/kg/day or approximately 
2% of the mother’s weight-adjusted dose [Notionn, 1984; Ostensen, 1985].  Routine eye 
exams of breastfed children are not indicated as the follow-up studies of exposed children 
are re-assuring [Costedoat, 2002].  
2.4.4 Corticosteroids 
Corticosteroids do not enter breast milk in large quantities.  The American Academy of 
Pediatrics has declared prednisone and prednisalone as safe and compatible with 
breastfeeding.  Infant exposure to prednisalone through breast milk can be minimized by 
dosing prednisalone at infrequent intervals and avoiding nursing for at least 4 hours 
following a dose [Alan Kamada, 1994] as peak milk steroid levels occurred approximately 2 
hours after a dose of prednisalone.  No data are available on the use of dexamethasone or 
betamethasone in lactating women. 
2.4.5 Cyclophosphamide 
Lactation is contraindicated during cyclophosphamide use as it is found in substantial 
concentrations in human breast milk [Wiernik, 1971].  Patient with life-threatening 
condition, who received cyclophosphamide during second or third trimester, their offspring 
should be monitored for immunosuppression and the development of secondary 
malignancies.  
2.4.6 Azathioprine (AZA) 
Nursing is not recommended in patients on AZA, because of the long-term potential of 
immunosuppression and carcinogenesis [Pediatrics, 1994], although, there were no reports 
to confirm this.  A report on a series of 4 patients treated with azathioprine while lactating, 
the breast milk samples were analyzed for 6-mercaptopurine (6-MP) in 2 of the mothers.  
Levels of 6-MP were undetectable.  Therefore, relative infant dose would have been less 
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than 0.09% of the maternal weight-adjusted dose.  No adverse effects were encountered in 
any of the 4 infants.  So, maternal azathioprine use during lactation does not appear to pose 
a significant immediate clinical risk to the suckling infant.  Continued monitoring and long-
term assessment of these infants are warranted [Moretti, 2006].  
2.4.7 Methotrexate 
The American Academy of Pediatrics considers methotrexate to be contraindicated during 
breastfeeding because of several patient problems, which include immunosuppression, 
neutropenia, adverse effects on growth, and carcinogenesis [Pediatrics, 1994].  So, 
breastfeeding during methotrexate treatment is not recommended. 
2.4.8 Cyclosporine 
The American Academy of Pediatrics considers cyclosporine to be contraindicated during 
lactation because of the potential long-term effects of immune-suppression, neutropenia, 
and a potential association with carcinogenesis [Pediatrics, 1994].  Breastfeeding should be 
discouraged in women using cyclosporine [Flecher, 1995]. 
2.4.9 Mycophenolate Mofetil (MMF) 
There is no enough data regarding the excretion of MMF into breast milk.  Lactation is not 
recommended while using MMF [EGRT, 2002]. 
2.4.10 Sulfasalazine 
This is compatible with nursing.  In eight mothers who were breastfeeding and taking 
sulfasalazine, analyses were done from mothers’ serum, breast milk and serum from their 
children. The results showed that the amount of sulfasalazine and sulfa pyridine 
transferred to the child in the breast milk is negligible with regards to the risk of 
kernicterus [Eshjorner, 1987].  
2.4.11 Tumor necrosis Factor α inhibitors (Anti-TNFα) 
At present it is not known whether TNF┙ inhibitors are secreted into breast milk and can be 
ingested by mothers with breastfed child.  Mothers who wish to breastfeed their children 
should be informed that there is insufficient knowledge to provide them with adequate 
information [Ostensen, 2008].  
2.4.12 Rituximab 
There is insufficient data to support breastfeeding in patients who are on Rituximab.  So it is 
better to avoid Rituximab during lactation.  
2.4.13 Intravenous Immunoglobulin (IVIG) 
No data regarding IVIG excretion in breast milk.  Therefore, we suggest avoiding 
breastfeeding while the patient is on IVIG. 
2.5 Safety of contraception in SLE women 
Premenopausal women with SLE should have access to safe and effective birth control 
measures.  Women who have diminished fertility may seek hormonal manipulation to 
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stimulate ovulation, and women receiving cyclophosphamide may need methods for 
preserving fertility.  Furthermore, exogenous estrogen may be used not only to prevent 
glucocorticoid-induced osteoporosis but also to treat ovarian cysts, endometriosis, irregular 
menses, and menorrhagia.  
The high rate of elective abortion among women with SLE may reflect the failure of the 
birth-control method used or the absence of an adequate birth-control program [Petri, 
2005; Leona, 1981]. As the disease activity during pregnancy is generally high in women 
who conceive, pregnancy can be particularly risky in women with active disease or on 
teratogenic medications. So, pregnancy should be planned to begin during period of 
disease quiescence making contraception an important issue for these women.  All 
women with rheumatologic disease have contraceptive options, including barrier 
methods, the intrauterine device (IUDs) and oral contraceptive pills (OCPs) [Wayslett, 
1991; Clowse, 2010]. 
Progestin-only contraceptives are not widely used because of their effects on the 
endometrial bleeding pattern [Mintz, 1984].  Oral contraceptives (OCPs) remain one of the 
most effective forms of birth control [Lauterbach, 2000]. The Safety of Estrogens in Lupus 
Erythematosus National Assessment (SELENA) trial of oral contraceptives versus placebo 
was a prospective, randomized, double blind trial that examined the effects of oral 
contraceptives (containing 35mg ethinyl estradiol) i.e. low estrogen dose on disease activity 
in 183 premenopausal women with SLE. This concluded with only 7 severe flares occurring 
in 91 patients receiving oral contraceptives, the same number which was recorded for the 92 
women receiving placebo.  To the surprise of most physicians, OCP was equivalent to 
placebo in terms of severe flares.  So, the available data support the use of OCPs containing 
estrogen as birth control choice for patients with inactive or stable SLE who are at low risk 
of thrombosis [Petri, 2005]. 
The SELENA trial does not pertain to women with very active SLE, such as active lupus 
nephritis, or those with the lupus anticoagulant or with high titer anticardiolipin, which 
were excluded. OCPs cannot be prescribed to all SLE women, but when appropriate, may 
demonstrably improve the quality of life [Petri, 2008].  Given the high prevalence of 
antiphospholipid antibodies in SLE, it seems prudent not to prescribe OCPs to women with 
lupus anticoagulant or medium-to-high titer anticardiolipin or anti-┚2 glycoprotein [Petri, 
2001].  Despite a lack of randomized studies, evidence strongly suggests that the elevated 
risk of thrombosis makes estrogen-containing contraceptives unsuitable for patients with 
APS, prior thromboembolic episodes, and severe migraine.  Decisions should be 
individualized according to the patients’ medical status, personal preference and stage of 
reproductive life [Sammaritano, 2007; Ashorson, 1986]. 
Another study evaluating the safety of OCP was conducted as a randomized, single-blinded 
12-month clinical trial in women with SLE to evaluate the effects on disease activity of 
combined oral contraceptives, as compared to progestin-only pill and IUD.  Disease activity 
remained mild and stable in all groups throughout the study.  There were no significant 
differences among the groups during the trial in disease activity, incidence or probability of 
flares on medication use.  Thromboses occurred in four patients (two in each of the two 
groups receiving hormones) [Sanchez, 2005]. 
The risk of infection associated with IUD insertion is too small to warrant routine use of 
prophylactic antibiotics. Recently, FDA removed immunosuppression from list of 
contraindications to IUD use. The use of combined oral contraceptives is possible in stable 
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premenopausal SLE, and who do not have any evidence of APS.  Lupus patients who are 
APL positive or have APS should be treated with progestogens only pills (oral or 
Parenteral) or IUD. 
2.6 Assisted reproductive therapy (ART) 
Young lupus patient exposed to I.V. cyclophosphamide face the risk of premature ovarian 
failure.  In vitro fertilization (IVF) and its associated technologies are used for infertility in 
patients with a wide range of etiologies, including those with SLE, and/or APS. 
The first phase of ART is ovulation induction followed by in vitro fertilization (IVF) and 
embryo transfer (ET) in the uterus.  The most threatening conditions in affected women 
undergoing ovarian stimulation are lupus flares and thrombosis, with the latter being 
especially associated with the occurrence of an overt ovarian hyper-stimulation syndrome 
(OHSS). 
SLE manifestations in acute flares, badly controlled arterial hypertension, pulmonary 
hypertension, advanced renal disease, severe valvulopathy or heart disease, and major 
previous thrombotic events are situations in which to ARTs are to be discouraged. It  
is especially due to the high risk of complications in both mother and fetus during 
pregnancy and puerpurium.  Therefore, ovarian stimulation for ovulation induction  
and IVF seems to be safe and successful in well-selected women with SLE and APS 
[Beliver, 2009]. 
The ovulation induction therapy (OIT) may precipitate SLE activity or APS.  A careful 
review of the patient’s history and appropriate laboratory tests should be undertaken before 
OIT.  Clomiphene adverse effects are rare.  When gonadotropins are prescribed, preventive 
anti-inflammatory therapy should be considered in women with SLE, in addition to heparin 
and/ or anti-aggregate therapy in patients with asymptomatic antiphospholipid antibodies 
or prior thrombotic events [Huong, 2002]. 
3. Pre-pregnancy counseling 
Couples with SLE with or without recurrent pregnancy loss require empathy and 
understanding as early pregnancy loss is an emotionally traumatic experience, similar to 
that associated with still birth. As many patients with SLE are young women in 
reproductive age and some being young men, wanted to have healthy children they need to 
be reassured that if they follow the expert doctor’s advice with careful follow-up during 
pregnancy, they could still have normal children. Therefore, one needs to stress the 
importance of preconception counseling (Table 4). 
3.1 Fertility  
The vast majority of patients have no problems with fertility. However occasionally  
some female patients may develop antibodies to ovarian tissue that interfere with 
development of ovum, others may have disrupted ovarian cycles which need further 
investigations. Infertility could be a problem in patients on long-term cyclophosphamide 
(more than 6 months) and its use can also cause congenital abnormalities. Therefore  
while the patients are on cyclophosphamide they need to be told to use reliable methods 
of contraception for the total duration on this drug and three months thereafter  
[Handa, 2006]. 
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Preconception counseling 
Assess for risk factors 
Stratify high/low risk 
Give realistic, evidence-based estimates for  likely  
          success and chance of problems 
Discuss prematurity and handicap 
Advise against pregnancy if appropriate 
Make and agree prospective plan of care 
Table 4. Preconception Counseling (Ruiz, 2008) 
For pregnancies with lupus, the risk of abortion, hypertension, and embryo deformity by a 
therapeutic agent is higher compared to healthy pregnancies. Lupus flares can occur at any 
time during pregnancy, as well as several months after delivery [Clowse, 2007]. Fortunately, 
the majority of gravidae do not have severe SLE activity but only mild flares mainly 
involving skin, joints, or constitutional symptoms [Izmirly, 2010]. 
Not all women with SLE have the same risk of complications during pregnancy. Thus, pre-
pregnancy counseling is essential to estimate the chance of both fetal and maternal mortality 
and morbidity (Table 4).  
To reduce the risk of pregnancy it is better to have a planned pregnancy. Therefore 
Pregnancy is usually undertaken when 
 The disease has been in remission for at least 6 months  
 Who require less than equivalent of 7.5  mg of prednisone per day 
 No previous renal disease, hypertension, thrombocytopenia or anti-phospholipid 
antibodies 
High-risk patients are shown in Table 5. 
An obstetrician experienced in management of high risk pregnancies is particularly desirable 
for women with one of these features for a better outcome of pregnancy. A previous 
complicated pregnancy is, by itself, an important adverse prognostic variable. Likewise, the 
presence of APS is closely associated with maternal thrombosis and embryo-fetal demise. 
Maternal anti-Ro and anti-La antibodies may cause congenital heart block in 2% of babies.  
This is fortunately a rare, but very serious condition, with a high mortality rate with or 
without cardiomyopathy and a high chance of permanent pacemaker for majority of 
children with CHB [Clowse, 2007). Defining a high risk pregnancy is not absolute as it 
differs from patient to patient due to the presence of other confounding factors. 
The testing for Anti-SSA/SSB/ U1RNP antibodies are done only in high risk population like 
Women with SLE, Sjogren’s syndrome, Undifferentiated connective tissue disease or other 
connective tissue diseases, since they comprise 50-60% of NLE mothers. It is also done in 
mothers with previous child having neonatal lupus as the risk of neonatal lupus in next 
pregnancy reaches up to 25%. 
Management of a case of APS is shown in the flow chart (figure 1). 
Chronic renal failure is also associated with other obstetric complications, such as 
hypertensive disorders and miscarriage, which are more likely to occur if renal impairment 
is more severe. Restrictive pulmonary disease may also worsen during pregnancy due to the 
thoracic compression by the growing uterus. Secondary APS is the main predictor of 
pregnancy complication in the form of miscarriage, fetal death, prematurity and 
preeclampsia. The disease activity has shown a clear association with fetal loss and 
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prematurity and the lupus anticoagulant confers the highest risk of miscarriages among the 
antibodies of APS [Handa, 2006]. 
 
High Risk Lupus Pregnancy 
Previous poor obstetric history 
Renal involvement 
Cardiac involvement 
Pulmonary hypertension 
Interstitial lung disease 
Active disease 
High-dose steroid therapy 
Other immune-suppressive therapy  
(cyclophosphamide, Methotrexate, etc) 
Antiphospholipid antibodies/syndrome 
Extractable nuclear antigens (Ro, La)  
Multiple pregnancy 
Table 5. High Risk Lupus Pregnancy  (Ruiz, 2008) 
 
 
                                                                  
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
ACL=anti-cardiolipin antibody; LAC=lupus anticoagulant 
Fig. 1. Flow Chart For Management Of APS Pregnant Patient (R. Handa, 2006) 
            ACL &/or LAC +ve 
No History of     
Pregnancy loss 
    History of  
  Pregnancy loss 
Low antibody titers 
LMWH +ASA 
High antibody   titers 
No Treatment ? ASA 80mg OD IVIG for refractory cases 
      Pregnant lupus patient 
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Contraindications to Pregnancy  in SLE 
(high maternal & fetal risk) 
Severe pulmonary hypertension  
       ( PAP >50 mm Hg or symptomatic) 
Restrictive lung disease (FVC <1 L) 
Heart failure 
Chronic renal impairment with Cr >250 µmols/L 
H/O  severe PET or HELLP  
       (despite ASA/LMWH) 
Stroke in <6 months 
Severe lupus flare in<6 months 
H/O arterial thrombosis or PE 
Table 6. Contraindications to pregnancy in SLE (Ruiz, 2008) 
 
 
Fig. 2. Flow chart for counseling and management of pregnancy in SLE 
6) BUN,
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In some extreme situations, the physicians should advise against pregnancy (Table 6).  
Women with current or recent lupus activity, particularly if affecting internal organs, should 
avoid pregnancy. The same recommendation applies to women with APS and recent 
thrombosis, particularly in the arterial bed. Women with severe kidney, lung or heart 
disease should also be discouraged from getting pregnant due to the high risk of maternal 
complications. Likewise, pregnancy should be considered an absolute contraindication in 
women with symptomatic severe pulmonary hypertension, which carries a higher than 30% 
maternal mortality during late pregnancy and the puerpurium.  
In patients having a serum creatinine over 250 µmols/L the chance of having a successful 
pregnancy is <30%. Despite aggressive treatment of secondary anti-phospholipid antibody 
syndrome the risk of thrombo-embolism and fetal death is still high. 
A major reason for discrepant results is in the definition of a lupus flare during pregnancy.  
In applying the Systemic Lupus Activity Measure (SLAM) to the pregnant lupus patient, 
fatigue, alopecia, decreased hematocrit, and increase ESR may not represent lupus activity. 
Suggestions for “valid” criteria attributable to a flare are characteristic dermatologic 
involvement, arthritis, hematuria, fever not secondary to infection, lymphadenopathy, 
leukopenia, alternative-pathway hypocomplementemia, and rising titers of antibodies to 
DNA. The patients with least risk in pregnancy are the patients who are in remission on < 
7.5 mg of prednesalone per day, normal renal functions, no proteinuria, normal blood 
counts, normal BP, normal levels of complement levels and no detectable dsDNA. 
The patients with moderate risk but still can be allowed to continue pregnancy with  
caution are- 
 Patients with mild flare with arthritis, mild pleuro-pericarditis, recalcitrant skin lesions, 
requiring 10-15 mg of prednisalone daily for continued symptoms. 
 Asymptomatic patients who have persistently elevated dsDNA and low levels of 
complement. 
Because SLE is a progressive disease and is not curable we should not stop the couples from 
going for children as delaying may cause them not to have children at all. Hence, to have 
children earlier is better than later. Therefore one should weigh the risks and benefits and 
involve the patients fully in decision making. 
Even platelets of 30,000-60,000, mild renal insufficiency (Cr=<200 µmols/L), proteinuria 1-
2gm/day may have greater risk of flare and fetal demise but still may have successful 
pregnancy. Therefore such woman needs to be counseled about high likelihood of 
premature delivery, preeclampsia and potential need for early hospitalization for delivery 
[Buyon, 2004]. 
The minimum diagnostic work up of the couples with SLE before preconception counseling 
includes, detail history taking including medical, surgical, genetic, obstetrical and family 
history as well as thorough physical examination. Complete antibody profile needs to be 
done [Anti-SSA/Ro, anti-SSB/La, anti-U1 RNP antibodies, ANA, dsDNA, etc]. Anti-
cardiolipin (ACL, both IgG & IgM), lupus anticoagulant (LA) are to be checked twice 6-8 
weeks apart to exclude false positive results. Anti-dsDNA and complement levels to be 
checked every trimester, to assess the activity of the disease, along with it test for 24 hr 
urinary protein and serum albumin [Clowse, 2007]. 
Patients who are positive to anti-SSA/SSB/U1RNP needs to follow the flow chart [figure 3] 
for diagnosis and management of CHB which is the common presentation and has the 
highest mortality and morbidity in neonatal lupus [Buyon, 2004]. 
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Screen for hypothyroidism as there is increased risk of miscarriage in subclinical 
hypothyroidism and incidence of hypothyroidism is found to be higher in SLE from recent 
studies. Test for diabetes mellitus and hyperprolactinemia and treat if present. If disease 
activity is present before pregnancy, the treatment needs to be started and patient should be 
free from disease activity at least for 6 months prior to pregnancy. 
 
 
Fig. 3. Decision tree for diagnosis & management of CHB  
High risk pregnancy needs a multi-disciplinary approach involving expert rheumatologist, 
experienced obstetrician skilled in managing high risk pregnancies, nephrologist, and 
neonatologist. Treatment of APS with aspirin or heparin as indicated before, during and 
after pregnancy.  
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The independent Risk Factors for pregnancy loss are Lupus activity in any trimester (but 
more in the first trimester), proteinuria, thrombocytopenia, hypertension in first trimester, 
APS and renal impairment, while the independent risk factors for pre-term delivery are 
increased lupus activity (before & during delivery), dose of prednisalone >7.5mg/day and 
hypertension [Ruiz, 2008). 
Finally patients with severe active disease, high degree of end organ damage such as severe 
PAH, CHF, severe restrictive pulmonary disease, severe chronic renal failure are advised 
against becoming pregnant as they are absolute contraindications. 
A significant rise in proteinuria and active sediment with or without falling complement 
values and rising DNA antibodies is justified to initiation the equivalent of 1 mg/kg per day 
of prednisalone. Moreover, the presence of proteinuria itself, even in the absence of active 
sediment, may warrant a trial of steroids. Persistent proteinuria > 3 grams/24 hr does not 
generally predict a good outcome for the mother or fetus. 
In the absence of any response within two weeks, a reassessment of the situation is 
warranted with consideration given to the addition of cytotoxic agents and early 
termination, especially in the setting of deteriorating renal function and an active urinary 
sediment. 
All patients have to practice hygienic way of living: No smoking, no alcohol, no recreational 
drugs, less caffeine consumption (<250mg/day) and to take folic acid supplements (at least 
400 mcg/ day). All the medications prescribed needs to be checked by her attending 
physician and approved [Ruiz, 2011; Izmirly, 2010)]. 
4. Conclusion 
Better outcome occurs by careful planning, patient education, close monitoring and 
aggressive management. All the above is important for a successful pregnancy outcome. 
Appropriate preconception counseling on management plans and shared care with special 
obstetrical & peri-natal attention will reduce the maternal and fetal morbidity and 
mortality. 
In pregnant lupus patients the medication has to be adjusted to the patient needs depending 
on the disease activity, prior obstetric history, presence or absence of APS, presence of anti-
SSA/Ro, SSB/La antibodies and the course of present pregnancy. So the disease 
manifestations, the course of pregnancy and the medications together will decide the 
morbidity of the mother and the child [Isenberg, 2004]. 
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